Keyphrases
Pulmonary Hypertension
70%
Checkpoint Inhibitor Pneumonitis
61%
Pulmonary Arterial Hypertension
48%
Hypoxia Model
47%
Non-small Cell Lung Cancer (NSCLC)
37%
SU5416
37%
Immune Checkpoint Inhibitors
36%
Vascular Endothelial Cells
32%
Pulmonary Artery Smooth muscle Cells (PASMCs)
30%
Caspase-3
29%
Immune Checkpoint
28%
Checkpoint Immunotherapy
28%
Aquaporin 1 (AQP1)
28%
Reactive Oxygen Species
27%
Transient Receptor Potential Vanilloid 4 (TRPV4)
26%
Hypoxia
25%
Sugen-hypoxia
25%
Immune-related Adverse Events
22%
Pneumonitis
21%
Endothelial Cells
20%
Lung Epithelial Cells
19%
Programmed Death-ligand 1 (PD-L1)
19%
Pulmonary Toxicity
18%
Disease States
18%
Transcript Level
18%
Fatty Acid Metabolism
18%
Lung
15%
Apoptosis
13%
Cluster of Differentiation 36 (CD36)
11%
Steroid-refractory
11%
Nuclear Translocation
11%
Ca2+ Influx
11%
Rat Model
11%
Pathobiology
10%
Survival Analysis
10%
Clinical Outcomes
10%
Negative Predictive Value
10%
Positive Predictive Value
10%
Apoptosis Resistance
10%
Pulmonary Circulation
10%
Transpulmonary
10%
Long-chain Fatty Acids
10%
Metabolism
9%
Comparison of Polynomials
9%
Non-apoptotic Functions
9%
Basic Scientist
9%
Nicotinamide Adenine Dinucleotide Phosphate Oxidase
9%
NSCLC Patients
9%
Consensus Definition
9%
Inhalation
9%
Medicine and Dentistry
Pneumonia
100%
Pulmonary Hypertension
69%
Immune Checkpoint Inhibitor
61%
Hypoxia
51%
Immunotherapy
39%
Lung Cancer
37%
Semaxanib
37%
Endothelial Cell
30%
Reactive Oxygen Species
29%
Pulmonary Toxicity
28%
Programmed Cell Death
23%
Disease
21%
Immune-Related Adverse Events
21%
Non Small Cell Lung Cancer
21%
Adverse Event
19%
Aquaporin 1
18%
Arterial Smooth Muscle Cell
18%
Calcium Ion
18%
Non-Small Cell Lung Cancer
16%
Malignant Neoplasm
15%
Neoplasm
13%
Vanilloid Receptor 4
13%
Caspase 3
11%
Nodular Melanoma
10%
Survival Analysis
10%
COVID-19
10%
Smooth Muscle Cell
10%
Programmed Death 1 Ligand 1
9%
Cell Proliferation
9%
Pulmonary Circulation
9%
Granulomatous Inflammation
9%
Endothelial Dysfunction
9%
Aspiration Cytology
9%
Lymphadenopathy
9%
Arterial Smooth Muscle
9%
Cancer Therapy
9%
Rheumatoid Arthritis
9%
Cancer Immunotherapy
9%
Regulatory T Cell
9%
Patient History of Radiotherapy
9%
Diethylstilbestrol
9%
Right Ventricular Function
9%
Calcium Transport
9%
Upregulation
9%
Placebo
9%
Acetazolamide
9%
Sarcoidosis
9%
Interstitial Lung Disease
9%
Radiation Therapy
9%
Endostatin
9%
